Steve Elms insider trades: Adma Biologics (ADMA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Steve reports to the SEC
and 17 more companies
Open-market buys and sales
37 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | ADMA | ↑ Buy | 14,000 | $15.53 | $217K | Indirect | Mar 9, 2026 (3d) |
| Jun 16, 2025 | ADMA | ↓ Sell | 332,680 | $20.48 | $6.8M | Direct | Jun 16, 2025 (0d) |
| Jun 12, 2025 | ADMA | ↓ Sell | 92,941 | $21.69 | $2.0M | Indirect | Jun 16, 2025 (4d) |
| Dec 23, 2024 | MRKR | ↑ Buy | 11,085 | $3.20 | $35K | Indirect | Dec 26, 2024 (3d) |
| Mar 19, 2024 | ADMA | ↓ Sell | 461,716 | $6.07 | $2.8M | Indirect | Mar 19, 2024 (0d) |
| Mar 15, 2024 | ADMA | ↓ Sell | 1,038,284 | $6.11 | $6.3M | Indirect | Mar 15, 2024 (0d) |
| Jun 29, 2021 | ELEV | ↑ Buy | 187,500 | $16.00 | $3.0M | Direct | Jul 1, 2021 (2d) |
| Mar 16, 2021 | MRKR | ↑ Buy | 1,142,857 | $1.75 | $2.0M | Indirect | Mar 18, 2021 (2d) |
| Jul 15, 2019 | SNSS | ↑ Buy | 2,500,000 | $0.60 | $1.5M | Indirect | Jul 15, 2019 (0d) |
| Jul 10, 2018 | LOXO | ↓ Sell | 1,400,000 | $179.43 | $251.2M | Direct | Jul 12, 2018 (2d) |
| Dec 19, 2017 | LOXO | ↓ Sell | 250,000 | $80.50 | $20.1M | Direct | Dec 20, 2017 (1d) |
| Nov 22, 2017 | LOXO | ↓ Sell | 500,000 | $75.00 | $37.5M | Direct | Nov 27, 2017 (5d) |
| Jan 10, 2017 | LOXO | ↑ Buy | 160,000 | $31.00 | $5.0M | Direct | Jan 12, 2017 (2d) |
| Jul 6, 2016 | SYRS | ↑ Buy | 400,000 | $12.50 | $5.0M | Direct | Jul 6, 2016 (0d) |
| May 17, 2016 | LOXO | ↑ Buy | 232,558 | $21.50 | $5.0M | Direct | May 19, 2016 (2d) |
| Dec 11, 2015 | LOXO | ↑ Buy | 200 | $27.50 | $6K | Direct | Dec 15, 2015 (4d) |
| Dec 9, 2015 | TTOO | ↑ Buy | 307,692 | $9.75 | $3.0M | Indirect | Dec 9, 2015 (0d) |
| Nov 17, 2015 | LOXO | ↑ Buy | 265,000 | $26.50 | $7.0M | Direct | Nov 19, 2015 (2d) |
| Nov 13, 2015 | LOXO | ↑ Buy | 78,669 | $27.65 | $2.2M | Direct | Nov 16, 2015 (3d) |
| Apr 24, 2015 | ESPR | ↓ Sell | 67,469 | $106.26 | $7.2M | By Aisling Capital II, LP | Apr 27, 2015 (3d) |
| Apr 23, 2015 | ESPR | ↓ Sell | 150,000 | $109.10 | $16.4M | By Aisling Capital II, L.P. | Apr 27, 2015 (4d) |
| Jan 27, 2015 | VSAR | ↑ Buy | 145,000 | $17.25 | $2.5M | See FN | Jan 29, 2015 (2d) |
| Jan 23, 2015 | AGRX | ↑ Buy | 811,966 | $5.85 | $4.8M | See FN | Jan 27, 2015 (4d) |
| Aug 12, 2014 | TTOO | ↑ Buy | 454,545 | $11.00 | $5.0M | Indirect | Aug 14, 2014 (2d) |
| Aug 6, 2014 | LOXO | ↑ Buy | 413,077 | $13.00 | $5.4M | Direct | Aug 6, 2014 (0d) |
| Aug 6, 2014 | LOXO | ↑ Buy | 413,077 | $13.00 | $5.4M | Held by Aisling Capital III, LP | Aug 6, 2014 (0d) |
| Apr 21, 2014 | TRXC | ↑ Buy | 1,037,767 | $4.00 | $4.2M | By Aisling Capital III, LP | Apr 23, 2014 (2d) |
| Mar 26, 2014 | VSAR | ↑ Buy | 60,000 | $21.00 | $1.3M | See FN | Mar 27, 2014 (1d) |
| Mar 21, 2014 | DRTX | ↓ Sell | 100,649 | $15.74 | $1.6M | By Aisling Capital III, LP | Mar 21, 2014 (0d) |
| Nov 14, 2013 | ZLTQ | ↓ Sell | 575,000 | $12.22 | $7.0M | By Aisling Capital III, LP | Nov 15, 2013 (1d) |
| Oct 22, 2013 | ADMA | ↑ Buy | 411,765 | $8.50 | $3.5M | By Aisling Capital II, LP | Oct 23, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 238,119 | $14.00 | $3.3M | By Aisling Capital II, L.P. | Jul 1, 2013 (0d) |
| May 21, 2013 | AMBI | ↑ Buy | 423,635 | $8.00 | $3.4M | Indirect | May 21, 2013 (0d) |
| Jul 24, 2012 | DRTX | ↑ Buy | 1,111,111 | $9.00 | $10.0M | By Aisling Capital III, LP | Jul 25, 2012 (1d) |
| Feb 7, 2012 | CEMP | ↑ Buy | 1,213,663 | $6.00 | $7.3M | By Aisling Capital II, LP | Feb 9, 2012 (2d) |
| Oct 24, 2011 | ZLTQ | ↑ Buy | 769,231 | $13.00 | $10.0M | Indirect | Oct 25, 2011 (1d) |
| Mar 10, 2010 | MAPP | ↓ Sell | 2,090 | $16.15 | $34K | Direct | Mar 12, 2010 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ADMA insiders
Open-market trades in the last 12 months
About Steve Elms's insider trades
Steve Elms is an insider at Adma Biologics (ADMA). Since Mar 10, 2010, Steve has reported 25 open-market purchases worth $99.8M and 12 sales worth $359.0M on SEC Form 4. In the last 12 months: 1 buy ($217K).
Their filings also include grants and awards (44 filings), other transactions (13 filings), conversions (11 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ADMA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.